Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 6
2004 5
2005 2
2006 6
2007 4
2008 8
2009 6
2010 9
2011 11
2012 6
2013 9
2014 12
2015 15
2016 13
2017 12
2018 23
2019 18
2020 14
2021 18
2022 13
2023 17
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Results by year

Filters applied: . Clear all
Page 1
Methodological innovations and stakeholder involvement in core outcome sets for skin diseases: a survey of the C3 working groups.
Ahmed A, Koza E, Shi V, Ma M, Haq M, Kottner J, Garg A, Ingram JR, Ezzedine K, Spuls PI, Beeckman D, Wolkenstein P, Fransen F, Noe MH, Langbroek GB, Bauer A, Thorlacius L, Horbach SER, Layton A, Apfelbacher C, Cahn BA, Pearlman R, Schlessinger DI, Alam M. Ahmed A, et al. Among authors: wolkenstein p. Arch Dermatol Res. 2024 Mar 18;316(4):109. doi: 10.1007/s00403-023-02812-1. Arch Dermatol Res. 2024. PMID: 38498269 No abstract available.
Whole-Body Positron Emission Tomography with 18F-Fluorodeoxyglucose/Magnetic Resonance Imaging as a Screening Tool for the Detection of Malignant Transformation in Individuals with Neurofibromatosis Type 1.
Fertitta L, Jannic A, Zehou O, Bergqvist C, Ferkal S, Moryousef S, Lerman L, Mulé S, Luciani A, Bapst B, Ezzedine K, Ortonne N, Itti E, Wolkenstein P. Fertitta L, et al. Among authors: wolkenstein p. J Invest Dermatol. 2024 Feb 17:S0022-202X(24)00112-X. doi: 10.1016/j.jid.2024.01.028. Online ahead of print. J Invest Dermatol. 2024. PMID: 38368929
Clinical relevance and uptake of core outcome sets in dermatology.
Ahmed A, Koza E, Shi V, Ma M, Haq M, Kottner J, Garg A, Ingram JR, Ezzedine K, Spuls PI, Beeckman D, Wolkenstein P, Fransen F, Noe MH, Langbroek GB, Bauer A, Thorlacius L, Horbach SER, Layton A, Apfelbacher C, Cahn BA, Pearlman R, Schlessinger DI, Alam M. Ahmed A, et al. Among authors: wolkenstein p. Arch Dermatol Res. 2024 Jan 20;316(2):78. doi: 10.1007/s00403-023-02814-z. Arch Dermatol Res. 2024. PMID: 38244063 No abstract available.
Breast cancer risk in NF1-deleted patients.
Pacot L, Masliah-Planchon J, Petcu A, Terris B, Gauthier Villars M, Lespinasse J, Wolkenstein P, Vincent-Salomon A, Vidaud D, Pasmant E. Pacot L, et al. Among authors: wolkenstein p. J Med Genet. 2024 Apr 19;61(5):428-429. doi: 10.1136/jmg-2023-109682. J Med Genet. 2024. PMID: 38154814 No abstract available.
Droplet Digital PCR for Fast and Accurate Characterization of NF1 Locus Deletions: Confirmation of the Predominant Maternal Origin of Type-1 Deletions.
Pacot L, Ye M, Nectoux J, Laurendeau I, Briand-Suleau A, Coustier A, Maillard T, Barbance C, Orhant L, Vaucouleur N, Blanché H, Parfait B, Wolkenstein P, Vidaud M; EURONET-NF; Vidaud D, Pasmant E. Pacot L, et al. Among authors: wolkenstein p. J Mol Diagn. 2024 Feb;26(2):150-157. doi: 10.1016/j.jmoldx.2023.11.005. Epub 2023 Nov 25. J Mol Diagn. 2024. PMID: 38008284 Free article.
A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials.
Fertitta L, Bergqvist C, Sarin KY, Plotkin SR, Moertel C, Petersen AK, Cannon A, Berman Y, Pichard DC, Röhl C, Lessing A, Brizion B, Peiffer B, Ravaud P, Tran VT, Armand ML, Moryousef S, Ferkal S, Jannic A, Ezzedine K, Wolkenstein P; Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) international collaboration. Fertitta L, et al. Among authors: wolkenstein p. Br J Dermatol. 2024 Jan 23;190(2):216-225. doi: 10.1093/bjd/ljad397. Br J Dermatol. 2024. PMID: 37877514
Identification of potential common genetic modifiers of neurofibromas: a genome-wide association study in 1333 patients with neurofibromatosis type 1.
Pacot L, Sabbagh A, Sohier P, Hadjadj D, Ye M, Boland-Auge A, Bacq-Daian D, Laurendeau I, Briand-Suleau A, Deleuze JF, Margueron R, Vidaud M, Ferkal S, Parfait B, Vidaud D; NF-France Network; Pasmant E, Wolkenstein P. Pacot L, et al. Among authors: wolkenstein p. Br J Dermatol. 2024 Jan 23;190(2):226-243. doi: 10.1093/bjd/ljad390. Br J Dermatol. 2024. PMID: 37831592
A Call for Discovery and Therapeutic Development for Cutaneous Neurofibromas.
Blakeley JO, Le LQ, Lee SY, Ly I, Rhodes SD, Romo CG, Sarin KY, Staedtke V, Steensma MR, Wolkenstein P; 2022 NTAP Cutaneous Neurofibroma Symposium Participants. Blakeley JO, et al. Among authors: wolkenstein p. J Invest Dermatol. 2023 Aug;143(8):1351-1357. doi: 10.1016/j.jid.2022.11.027. Epub 2023 Jun 21. J Invest Dermatol. 2023. PMID: 37354152 No abstract available.
206 results